<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A vaccine derived from the high-molecular-weight <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (gp340) component of the Epstein-Barr (EB) virus membrane antigen conferred complete protection against a 100% lymphomagenic dose of EB virus in the cottontop tamarin, the animal of choice for experiments with EB virus </plain></SENT>
<SENT sid="1" pm="."><plain>The membrane-antigen gene has already been cloned, and the development of a vaccine for use in man should now be possible </plain></SENT>
<SENT sid="2" pm="."><plain>Such a vaccine could be tested first against <z:e sem="disease" ids="C0021345" disease_type="Disease or Syndrome" abbrv="">infectious mononucleosis</z:e>, because the effectiveness of vaccination would become evident in a relatively short time </plain></SENT>
<SENT sid="3" pm="."><plain>Field trials against Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:e sem="disease" ids="C0153392" disease_type="Neoplastic Process" abbrv="">nasopharyngeal cancer</z:e> could follow </plain></SENT>
</text></document>